Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Governance document

Draft policy: labelling of Institute-constructed programme records

Consultation on how the Institute should label a programme record it has constructed by grouping trials, as distinct from a programme as defined by its sponsor. The draft proposes a standing notice on every constructed record stating who constructed it and on…

Document identifier
CEI-CP-013
Series
Public comment period
Version
1.0
Published
05 Jan 2025
Last reviewed
05 Jan 2025
Next review
05 Jan 2026
Identifier
10.71829/cei.cp.13
Certainty
Not rated
Cycle
2024 Q4
Window
01 Nov 2024 – 01 Dec 2024
Status
Closed
Submissions
13

§1Consultation and window

§1.1Window

Opened
1 November 2024
Closed
1 December 2024
Duration
30 days
Status
Closed — the disposition is published
Document under consultation
Governance document
Submissions received
13

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is a standing notice sufficient, or should a constructed record be visually distinguished from a sponsor-defined one throughout?
  2. Should the Institute publish its grouping criteria in full, including the cases where a trial was considered and excluded from a programme?
  3. Does the draft state clearly enough that a constructed programme record is a finding aid and not a sponsor document?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The policy was ratified with amendments. Constructed records now carry both the standing notice and a distinct visual treatment, and the grouping criteria are published with the trials considered and excluded.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.